Sutro Biopharma (STRO) Return on Equity (2018 - 2025)
Sutro Biopharma's Return on Equity history spans 8 years, with the latest figure at 3.4% for Q3 2025.
- For Q3 2025, Return on Equity rose 434.0% year-over-year to 3.4%; the TTM value through Sep 2025 reached 3.4%, up 434.0%, while the annual FY2024 figure was 2.34%, 176.0% down from the prior year.
- Return on Equity for Q3 2025 was 3.4% at Sutro Biopharma, down from 6.99% in the prior quarter.
- Across five years, Return on Equity topped out at 6.99% in Q2 2025 and bottomed at 25.45% in Q1 2025.
- The 5-year median for Return on Equity is 0.65% (2022), against an average of 1.46%.
- The largest YoY upside for Return on Equity was 799bps in 2025 against a maximum downside of -2452bps in 2025.
- A 5-year view of Return on Equity shows it stood at 0.37% in 2021, then tumbled by -44bps to 0.53% in 2022, then crashed by -53bps to 0.82% in 2023, then crashed by -258bps to 2.92% in 2024, then surged by 216bps to 3.4% in 2025.
- Per Business Quant, the three most recent readings for STRO's Return on Equity are 3.4% (Q3 2025), 6.99% (Q2 2025), and 25.45% (Q1 2025).